Kip Piper's Health Care Blog
Medicare, Medicaid, Health Reform

The massive reforms to Medicare physician reimbursement mandated under Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) present many issues and opportunities for accountable care organizations (ACOs) participating in the Medicare Shared Savings Program (MSSP).  While moving Medicare Part B to a new merit-based system of physician and clinic payment, MACRA also...
Creating a wellness-based healthcare system is the focus on a new series of articles published by American Health and Drug Benefits, a peer reviewed journal. They cover a wide spectrum of topics on how to build and support prevention and wellness, particularly for chronic conditions. The ideas and information...
Health care payment reform efforts focus on substituting cost-effective value for volume and ultimately aligning the financial incentives of provider reimbursement with expectations for patient outcomes, care management, and efficiency.  The complex dynamics and trade-offs of different payment reform models are discussed in a helpful new report from the Urban Institute...
The life sciences companies are looking for new board members and senior executives - and today's challenging business, payor, and regulatory environment requires new skills.  In a new episode of the MediStrategy podcast, learn how pharmaceutical, biotechnology, medical diagnostics, and medical device firms find new board directors, chief executive...
As policymakers in Washington argue over the best way to reform America's health care system, a compelling new book by Eric Topol, MD, suggests that the advance of technology is going to change how health care services are delivered in more profound and unpredictable ways than most people can...
Real-World Evidence for Drugs, Biologics, Medical Diagnostics, and Devices. Blog post by Kip Piper.
Insights from Experts Convened by the U.S. Food and Drug Administration (FDA) and the National Academies of Sciences, Engineering, and Medicine. Historically, randomized controlled trials have been used to determine the effectiveness and potential uses of biopharmaceutical products and medical treatments. These...
Use of Medicines in 2019 and Forecasts for 2023 Drugs and Biologics
Biopharmaceutical Spending Increasing but at Slower Annual Growth Rate  The pharmaceutical market is set to reach $1.5 trillion globally by the year 2023, according to a new report by the IQVIA Institute for Human Data Science and entitled The Global Use of Medicine in...
Medicare Episode-Based Payment Reform Demonstrations GAO Review of Voluntary and Mandatory Models
The Centers for Medicare and Medicaid Services (CMS) is investigating the effects of different episode-based payment methodologies on health care cost efficiency and quality in the Medicare program. A new report released by the U.S. Government Accountability Office (GAO) details the results of some of CMS' most...
Global drug pricing continues to ignite fresh controversies as health policy makers, government health programs, health insurers, and pharmaceutical companies meet in heated debate. Solutions for health around the world rely on stakeholders having a clear understanding of the structure and logic behind drug pricing, but the complexities of the...
The research and development pipeline for drugs and biologics is experiencing a tremendous surge in innovation, which will come to fruition within the next five years. This surge in prescription medicines will parallel a number of technology-enabled transformations in health care delivery that will dramatically increase access to health...

Stay Connected

4,688FansLike
6,951FollowersFollow
21,519FollowersFollow

Latest Articles